327 related articles for article (PubMed ID: 21122554)
1. Hepatosplenic T-cell lymphoma and inflammatory bowel disease.
Thai A; Prindiville T
J Crohns Colitis; 2010 Nov; 4(5):511-22. PubMed ID: 21122554
[TBL] [Abstract][Full Text] [Related]
2. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
4. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.
Mackey AC; Green L; Liang LC; Dinndorf P; Avigan M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):265-7. PubMed ID: 17255842
[TBL] [Abstract][Full Text] [Related]
5. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.
Ochenrider MG; Patterson DJ; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):144-8. PubMed ID: 20371449
[TBL] [Abstract][Full Text] [Related]
6. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
7. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Shah ED; Coburn ES; Nayyar A; Lee KJ; Koliani-Pace JL; Siegel CA
Aliment Pharmacol Ther; 2020 Mar; 51(5):527-533. PubMed ID: 31990422
[TBL] [Abstract][Full Text] [Related]
8. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?
Subramaniam K; Yeung D; Grimpen F; Joseph J; Fay K; Buckland M; Talaulikar D; Elijah J; Clarke AC; Pavli P; Moore J
Intern Med J; 2014 Mar; 44(3):287-90. PubMed ID: 24621284
[TBL] [Abstract][Full Text] [Related]
9. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.
Yabe M; Medeiros LJ; Daneshbod Y; Davanlou M; Bueso-Ramos CE; Moran EJ; Young KH; Miranda RN
Ann Diagn Pathol; 2017 Feb; 26():16-22. PubMed ID: 28038706
[TBL] [Abstract][Full Text] [Related]
10. Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.
van de Meeberg MM; Derikx LA; Sinnige HA; Nooijen P; Schipper DL; Nissen LH
World J Gastroenterol; 2016 Dec; 22(47):10465-10470. PubMed ID: 28058028
[TBL] [Abstract][Full Text] [Related]
11. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.
Mackey AC; Green L; Leptak C; Avigan M
J Pediatr Gastroenterol Nutr; 2009 Mar; 48(3):386-8. PubMed ID: 19274799
[No Abstract] [Full Text] [Related]
12. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
Rosh JR; Gross T; Mamula P; Griffiths A; Hyams J
Inflamm Bowel Dis; 2007 Aug; 13(8):1024-30. PubMed ID: 17480018
[TBL] [Abstract][Full Text] [Related]
13. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.
Selvaraj SA; Chairez E; Wilson LM; Lazarev M; Bass EB; Hutfless S
Syst Rev; 2013 Jul; 2():53. PubMed ID: 23826928
[TBL] [Abstract][Full Text] [Related]
14. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients?
Beyer M; Steinhoff M; Anagnostopoulos I; Assaf C; Sterry W
J Dtsch Dermatol Ges; 2009 Mar; 7(3):191-4. PubMed ID: 19192165
[TBL] [Abstract][Full Text] [Related]
15. Lymphomas in two IBD patients treated with anti-TNF-α mono or combination therapy: is hepatosplenic lymphoma really the "old maid"?
Molnár T; Farkas K; Nagy F; Szepes Z; Wittmann T
Inflamm Bowel Dis; 2011 Sep; 17(9):2025-6. PubMed ID: 21290481
[No Abstract] [Full Text] [Related]
16. Hepatosplenic and other gammadelta T-cell lymphomas.
Vega F; Medeiros LJ; Gaulard P
Am J Clin Pathol; 2007 Jun; 127(6):869-80. PubMed ID: 17509984
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
Wang Q; Jiang Y; Zhu Q; Duan Y; Chen X; Xu T; Jin Z; Li C; Wu D; Huang H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3441-3445. PubMed ID: 33856526
[TBL] [Abstract][Full Text] [Related]
18. Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant.
Bašić Kinda S; Duraković N; Dotlić S; Serventi Seiwerth R; Davidović Mrsić S; Dubravčić K; Aurer I
Leuk Lymphoma; 2013 Jun; 54(6):1334-5. PubMed ID: 23083012
[No Abstract] [Full Text] [Related]
19. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
Rosh JR; Oliva-Hemker M
J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):165-7. PubMed ID: 17255825
[No Abstract] [Full Text] [Related]
20. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.
Drini M; Prichard PJ; Brown GJ; Macrae FA
Med J Aust; 2008 Oct; 189(8):464-5. PubMed ID: 18928444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
